Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S ≤1-- A Prospective Randomized Study Comparing With alpha-blockers

Next Previous
Search
Trial Profile

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S ≤1-- A Prospective Randomized Study Comparing With alpha-blockers

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolterodine (Primary) ; Doxazosin
  • Indications Lower urinary tract symptoms
  • Focus Therapeutic Use

Most Recent Events

  • 02 May 2013 Status changed from completed to active no longer recruiting, after contacting the author and the author saying that final results have not come out yet.
  • 18 Mar 2013 Interim results (n=139) presented at the 28th Congress of the European Association of Urology.
  • 19 Oct 2012 Results presented at the 42nd Annual Meeting of the International Continence Society.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top